References

1. Zimetbaum P, Josephson ME. Evaluation of patients with palpitations. N Engl J Med 1998;338:1369-1373.

2. Kapoor WN, Karpf M, Wieand S, Peterson JR, Levey GS. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983;309:197-204.

3. Day SC, Cook EF, Funkenstein H, Goldman L. Evaluation and outcome of emergency room patients with transient loss of consciousness. Am J Med 1982;73:15-23.

4. VarmaN, Josephson ME. Therapy of "idiopathic" ventricular tachycardia. J Cardiovasc Electrophysiol 1997;8:104-116.

5. Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. 3rd ed. Philadelphia, PA, 2000, pp. 597-615.

6. Josephson ME, Wellens HJ. Differential diagnosis of supraventricular tachycardia. Cardiol Clin 1990;8:411-442.

7. Holter NJ. New method for heart studies: continuous electrocardiography of active subjects over long periods is now practical. Science 1961;134:1214-1220.

8. Krahn AD, Klein GJ, Norris C, Yee R. The etiology of syncope in patients with negative tilt table and electrophysiological testing. Circulation 1995;92:1819-1824.

9. Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for Ambulatory Electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). Developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol 1999;34:912-948.

10. Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med 1999;130:848-856.

11. Zimetbaum PJ, Kim KY, Josephson ME, Goldberger AL, Cohen DJ. Diagnostic yield and optimal duration of continuous-loop event monitoring for the diagnosis of palpitations. A cost-effectiveness analysis. Ann Intern Med 1998;128:890-895.

12. Reiffel JA, Schulhof E, Joseph B, Severance E, Wyndus P, McNamara A. Optimum duration of transtelephonic ECG monitoring when used for transient symptomatic event detection. J Electrocardiol 1991;24:165-168.

13. Zimetbaum P, Kim KY, Ho KK, Zebede J, Josephson ME, Goldberger AL. Utility of patient-activated cardiac event recorders in general clinical practice. Am J Cardiol 1997;79:371-372.

14. Kinlay S, Leitch JW, Neil A, Chapman BL, Hardy DB, Fletcher PJ. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in patients with palpitations. A controlled clinical trial. Ann Intern Med 1996;124:16-20.

15. DiMarco JP, Philbrick JT. Use of ambulatory electrocardiographic (Holter) monitoring. Ann Intern Med 1990;113:53-68.

16. Bass EB, Curtiss EI, Arena VC, et al. The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 1990;150:1073-1078.

17. Brown AP, Dawkins KD, Davies JG. Detection of arrhythmias: use of a patient-activated ambulatory electrocardiogram device with a solid-state memory loop. Br Heart J 1987;58:251-253.

18. Linzer M, Pritchett EL, Pontinen M, McCarthy E, Divine GW. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol 1990;66:214-219.

19. Krahn AD, Klein GJ, Yee R, Takle-Newhouse T, Norris C. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation 1999;99:406-410.

20. Krahn AD, Klein GJ, Yee R, Manda V. The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope. Am Heart J 1999;137:870-877.

21. Benditt DG, Ferguson DW, Grubb BP, et al. Tilt table testing for assessing syncope. American College of Cardiology. J Am Coll Cardiol 1996;28:263-275.

22. Kapoor WN, Brant N. Evaluation of syncope by upright tilt testing with isoproterenol. A nonspecific test. Ann Intern Med 1992;116:358-363.

23. Kapoor WN, Smith MA, Miller NL. Upright tilt testing in evaluating syncope: a comprehensive literature review. Am J Med 1994;97:78-88.

24. Anderson KP, DeCamilla J, Moss AJ. Clinical significance of ventricular tachycardia (3 beats or longer) detected during ambulatory monitoring after myocardial infarction. Circulation 1978;57:890-897.

25. Buxton AE, Marchlinski FE, Waxman HL, Flores BT, Cassidy DM, Josephson ME. Prognostic factors in nonsustained ventricular tachycardia. Am J Cardiol 1984;53:1275-1279.

26. Bigger JT, Jr., Fleiss JL, Rolnitzky LM. Prevalence, characteristics and significance of ventricular tachycardia detected by 24-hour continuous electrocardiographic recordings in the late hospital phase of acute myocardial infarction. Am J Cardiol 1986;58:1151-1169.

27. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984;54:31-36.

28. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-1940.

29. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-1890.

30. Naccarelli GV, Wolbrette DL, Dell'Orfano JT, Patel HM, Luck JC. A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyar-rhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators. J Cardiovasc Electrophysiol 1998;9:864-891.

31. Huang SK, Messer JV, Denes P. Significance of ventricular tachycadiain idiopathic dilated cardiomyopathy: observations in 35 patients. Am J Cardiol 1983;51:507-512.

32. Suyama A, Anan T, Araki H, Takeshita A, Nakamura M. Prevalence of ventricular tachycardia in patients with different underlying heart diseases: a study by Holter ECG monitoring. Am Heart J 1986;112:44-51.

33. Neri R, Mestroni L, Salvi A, Pandullo C, Camerini F. Ventricular arrhythmias in dilated cardiomyopathy: efficacy of amiodarone. Am Heart J 1987;113:707-715.

34. Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984;53:902-907.

35. Holmes J, Kubo SH, Cody RJ, Kligfield P. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. Am J Cardiol 1985; 55:146-151.

36. Chakko CS, Gheorghiade M. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy. Am Heart J 1985;109:497-504.

37. Wilson JR, Schwartz JS, Sutton MS, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983;2:403-410.

38. Singh SN, Fletcher RD, Fisher S, et al. Veterans Affairs congestive heart failure antiarrhythmic trial. CHF STAT Investigators. Am J Cardiol 1993;72:99F-102F.

39. Massie BM, Fisher SG, Radford M, et al. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators (published erratum appears in Circulation 1996; Nov 15;94[10]:2668). Circulation 1996;93:2128-2134.

40. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure [see comments]. N Engl J Med 1991;325:303-310.

41. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-498.

42. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. Circulation 1996;94:3198-3203.

43. Singh SN, Fisher SG, Carson PE, Fletcher RD. Prevalence and significance of nonsustained ventricular tachycardia inpatients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators. J Am Coll Cardiol 1998;32:942-947.

44. Sim I, McDonald KM, Lavori PW, Norbutas CM, Hlatky MA. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation 1997;96:2823-2829.

45. Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995;92:1680-1692.

46. Knoebel SB, Crawford MH, Dunn MI, et al. Guidelines for ambulatory electrocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Ambulatory Electrocardi-ography). Circulation 1989;79:206-215.

47. Spirito P, Rapezzi C, Autore C, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994;90:2743-2747.

48. Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemody-namic, and electrophysiological findings. Circulation 1992;86:730-740.

49. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 1998; 79:331-336.

50. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000; 342:365-373.

51. McKennaWJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11:147-153.

52. Pinsky WW, Arciniegas E. Tetralogy of Fallot. Pediatr Clin N Am 1990;37:179-192.

53. Chandar JS, Wolff GS, Garson A, Jr., et al. Ventricular arrhythmias in postoperative tetralogy of Fallot. Am J Cardiol 1990;65:655-661.

54. Joffe H, Georgakopoulos D, Celemajer DS, Sullivan ID, Deanfield JE. Late ventricular arrhythmia is rare after early repair of tetralogy of Fallot. J Am Coll Cardiol 1994;23:1146-1150.

55. Cullen S, Celermajer DS, Franklin RC, Hallidie-Smith KA, Deanfield JE. Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study. J Am Coll Cardiol 1994;23:1151-1155.

56. Marelli A, Moodie D. Adult congenital heart disease. In: Topol E, ed. Textbook of Cardiovascular Medicine. Lippincott-Raven, Philadelphia, PA, 1998, pp. 769-797.

57. Schwartz PJ. The long QT syndrome. Curr Probl Cardiol 1997;22:297-351.

58. Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995;122:701-714.

59. Eggeling T, Osterhues HH, Hoeher M, Gabrielsen FG, Weismueller P, Hombach V. Value of Holter monitoring in patients with the long QT syndrome. Cardiology 1992;81:107-114.

60. Locati EH, Maison-Blanche P, Dejode P, Cauchemez B, Coumel P. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J Am Coll Cardiol 1995;25:1564-1575.

61. Michaelsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 1995;92:442-449.

62. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med 1987;316:835-839.

63. Gregoratos G, Cheitlin MD, Conill A, et al. ACC/AHA Guidelines for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices: Executive Summary—a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). Circulation 1998;97:1325-1335.

64. Borggrefe M, Fetsch T, Martinez-Rubio A, Makijarvi M, Breithardt G. Prediction of arrhythmia risk based on signal-averaged ECG in postinfarction patients. Pacing Clin Electrophysiol 1997;20:2566-2576.

65. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987;9:531-538.

66. Cripps T, Bennett D, Camm J, Ward D. Prospective evaluation of clinical assessment, exercise testing and signal-averaged electrocardiogram in predicting outcome after acute myocardial infarction. Am J Cardiol 1988;62:995-999.

67. el-Sherif N, Ursell SN, Bekheit S, et al. Prognostic significance of the signal-averaged ECG depends on the time of recording in the postinfarction period. Am Heart J 1989;118:256-264.

68. Breithardt G, Schwarzmaier J, Borggrefe M, Haerten K, Seipel L. Prognostic significance of late ventricular potentials after acute myocardial infarction. Eur Heart J 1983;4:487-495.

69. Gomes JA, Winters SL, Stewart D, Horowitz S, Milner M, Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987;10:349-357.

70. Signal-averaged electrocardiography. J Am Coll Cardiol 1996;27:238-249.

71. Hohnloser SH, Klingenheben T, Zabel M, Li YG. Heart rate variability used as an arrhythmia risk stratifier after myocardial infarction. Pacing Clin Electrophysiol 1997;20:2594-2601.

72. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992;85:177-191.

73. Bigger JT, Jr., Kleiger RC, Fleiss JL, Rolnitzky LM, Steinman RC, Miller JP. Components of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol 1988;61:208-215.

74. Bigger JT, Jr., Fleiss JL, Rolnitzky LM, Steinman RC, Schneider WJ. Time course of recovery of heart period variability after myocardial infarction. J Am Coll Cardiol 1991;18:1643-1649.

75. Kleiger RE, Miller JP, Bigger JT, Jr., Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987;59:256-262.

76. Odemuyiwa O, Malik M, Farrell T, Bashir Y, Poloniecki J, Camm J. Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 1991;68:434-439.

77. Bigger JT, Jr., Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992;85:164-171.

78. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991;18:687-693.

79. Armoundas AA, Osaka M, Mela T, et al. T-wave alternans and dispersion of the QT interval as risk stratification markers in patients susceptible to sustained ventricular arrhythmias. Am J Cardiol 1998;82:1127-1129.

80. Russell DC, Smith JH, Oliver MF. Transmembrane potential changes and ventricular fibrillation during repetitive myocardial ischemia in the dog. Br Heart J 1979;42:88-96.

81. Downar E, Janse MJ, Durrer D. The effect of acute coronary artery occlusion on subepicardial transmembrane potentials in the intact porcine heart. Circulation 1977;56:217-224.

82. Murda'h MA, McKenna WJ, Camm AJ. Repolarization alternans: techniques, mechanisms, and cardiac vulnerability. Pacing Clin Electrophysiol 1997;20:2641-2657.

83. Salerno JA, Previtali M, Panciroli C, et al. Ventricular arrhythmias during acute myocardial ischaemia in man. The role and significance of R-ST-T alternans and the prevention of ischaemic sudden death by medical treatment. Eur Heart J 1986;(7 Suppl A):63-75.

84. Joyal M, Feldman RL, Pepine CJ. ST-segment alternans during percutaneous transluminal coronary angioplasty. Am J Cardiol 1984;54:915-916.

85. Kleinfeld MJ, Rozanski JJ. Alternans of the ST segment in Prinzmetal's angina. Circulation 1977; 55:574-577.

86. Hohnloser SH, Klingeheben T, Zabel M, et al. Heart rate threshold is important for detecting T wave alternans (abstract). PACE 1996;19:II-588.

87. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994;330:235-241.

88. Estes MNA, Zipes DP, el-Sherif N, et al. Electrical alternans during rest and exercise as a predictor of vulnerability to ventricular arrhythmias. J Am Coll Cardiol 1995; Special Issue:409A.

89. Murda'h M, Nagayoshi H, Albrecht P, et al. T-wave alternans as a predictor of sudden death in hypertrophic cardiomyopathy (abstract). Circulation 1996;94(Suppl.):I-669.

90. de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998;97:467-472.

91. Okin PM, Devereux RB, Howard BV, Fabsitz RR, Lee ET, Welty TK. Assessment of QT Interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study. Circulation 2000 Jan 4;101:61-66.

92. Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994;89:1681-1689.

93. Zareba W, Moss AJ, le Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994;74:550-553.

94. Zabel M, Klingenheben T, Franz MR, Hohnloser SH. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study. Circulation 1998;97:2543-2550.

95. Spargias KS, Lindsay SJ, Kawar GI, et al. QT dispersion as a predictor of long-term mortality in patients with acute myocardial infarction and clinical evidence of heart failure [see comments]. Eur Heart J 1999;20:1158-1165.

96. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-329.

97. Brooksby P, Batin PD, Nolan J, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The United Kingdom heart failure evaluation and assessment of risk trial (UK-HEART) [see comments]. Eur Heart J 1999;20:1335-1341.

98. Yi G, Ellioitt P, McKenna WJ, et al. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 1998;82:1514-1519.

99. Mandel W, Hayakawa H, Danzig R, Marcus HS. Evaluation of sino-atrial node function in man by overdrive suppression. Circulation 1971;44:59-66.

100. Strauss HC, Saroff AL, Bigger JT, Jr., Giardina EG. Premature atrial stimulation as a key to the understanding of sinoatrial conduction in man. Presentation of data and critical review of the literature. Circulation 1973;47:86-93.

101. Strauss HC, Bigger JT, Saroff AL, Giardina EG. Electrophysiologic evaluation of sinus node function in patients with sinus node dysfunction. Circulation 1976;53:763-776.

102. Scheinman MM, Peters RW, Modin G, Brennan M, Mies C, O'Young J. Prognostic value of intranodal conduction time in patients with chronic bundle branch block. Circulation 1977;56:240-244.

103. McAnulty JH, Rahimtoola SH, Murphy E, et al. Natural history of "high-risk" bundle-branch block: final report of a prospective study. N Engl J Med 1982;307:137-143.

104. Dhingra RC, Palileo E, Strasberg B, et al. Significance of the HV interval in 517 patients with chronic bifascicular block. Circulation 1981;64:1265-1271.

105. Myerburg RJ, Castellanos A. Evolution, evaluation, and efficacy of implantable cardioverter-defibrillator technology [editorial; comment]. Circulation 1992;86:691-693.

106. Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations. 2nd ed. Lea & Febiger, Philadelphia, PA, 1993, pp. 1-839.

107. ACC/AHA Task Force Report. Guidelines for Clinical Intracardiac Electrophysiological and Catheter Ablation Procedures. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures). Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Cardiovasc Electrophysiol 1995;6:652-679.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook


Post a comment